AAOI vs CWAN

AAOI's deterministic health scores are severely compromised: the Piotroski F-Score of 0/9 signals extreme financial distress, with no positive indicators in profitability, leverage, or cash flow. The Altman Z-Score is unavailable, but the company's negative ROE (-7.94%), negative profit margins (-8.39%), and persistent losses despite 33.9% revenue growth indicate deep operational inefficiency. While the stock has delivered extraordinary price appreciation (510% in 1Y), this is not supported by fundamentals, and the valuation (P/E 30.28, Price/Sales 15.97) reflects a premium driven by speculative momentum rather than intrinsic value. Insider selling of $23.77M in the last 6 months further undermines confidence, signaling potential misalignment with public investors.

CWAN exhibits a critical disconnect between explosive top-line growth and fundamental financial health, evidenced by a weak Piotroski F-Score of 2/9. While revenue growth is an impressive 72% YoY, the valuation is severely stretched with a PEG ratio of 10.15 and a Price/Sales ratio of 9.83. This fundamental weakness is compounded by aggressive insider selling from the CEO, CFO, and CTO, and a bearish technical trend. Despite a consistent track record of earnings beats, the lack of GAAP profitability and poor deterministic health scores suggest the stock is significantly overvalued.